Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
NCT00885872Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2009
- Primary completion
- Mar 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rosuvastatin in atherosclerosis and hyperlipidemia, sponsored by Chinese PLA General Hospital. Primary endpoint: Change in the percentage of volume of lipid rich necrotic core (LRNC) at 2 years. Status: unknown.
02
Drugs
rosuvastatin
03
Conditions
atherosclerosishyperlipidemia
Beyond the preview
Go deeper on NCT00885872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885872.